The composition of matter patent is a foundational IP event that de-risks the forazapadin program's commercial runway. Monitor upcoming Phase 2 data readouts from BASECAMP and TRAILHEAD, as well as the initiation of the FSHD Phase 2 study in Q4 2026, for catalysts that could further validate the platform.
Price Chart
Executive Summary
Satellos announced the USPTO issued U.S. Patent No. 12,747,245 with composition of matter claims covering its lead drug candidate forazapadin and related AAK1 inhibitors, providing IP protection through September 6, 2044, with potential for Patent Term Extension. The patent strengthens the company's intellectual property estate as forazapadin advances in Phase 2 trials for Duchenne muscular dystrophy and is expected to begin a Phase 2 study in facioscapulohumeral muscular dystrophy in Q4 2026.
Key Facts
- USPTO issued U.S. Patent No. 12,747,245 with composition of matter claims covering forazapadin and a broader class of AAK1 inhibitors.
- Composition of matter patent provides IP protection through September 6, 2044, with potential Patent Term Extension after U.S. marketing approval.
- Forazapadin is in ongoing Phase 2 clinical studies: BASECAMP (pediatric DMD, randomized placebo-controlled) and TRAILHEAD (adult DMD, open-label).
- A Phase 2 study for forazapadin in adults with FSHD is expected to begin in Q4 2026.
- Company intends to seek Orange Book listing for the patent following potential U.S. marketing approval.
Financial Impact
No financial figures disclosed; patent strengthens long-term commercial exclusivity for forazapadin, a clinical-stage asset with no approved product or revenue.
Risk Factors
- Forazapadin is still in Phase 2 development with no approved product; clinical failure or regulatory setbacks could render the patent valueless.
- Patent Term Extension and Orange Book listing are contingent on future U.S. marketing approval, which is uncertain and years away.
- The company may require additional financing to complete clinical development, which could cause dilution.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006380 |
| Document: f6k_100226.htm | 0001171843-26-006380 |
| Document: 0001171843-26-006380-index-headers.html | 0001171843-26-006380 |
| Document: 0001171843-26-006380-index.html | 0001171843-26-006380 |
| Document: 0001171843-26-006380.txt | 0001171843-26-006380 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.54 (+1.87%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.54 (−2.39%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.54 (−18.76%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.54 (−30.13%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.54 (−34.73%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.54 (−27.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers